Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Nishioka, M. Azuma, Y. Aono, H. Makino, K. Kinoshita, H. Uehara, K. Izumi, S. Sone (Tokushima, Japan). Roles of α1-acid glycoprotein in therapeutic effects of imatinib in bleomycin-induced pulmonary fibrosis: benefits of macrolides. Eur Respir J 2007; 30: Suppl. 51, 1841

Member's Comments

No comment yet.

Related content which might interest you: Estimation of antibiotic effect on the development of bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 A translational value of pulmonary function tests in a mouse model of bleomycin-induced pulmonary fibrosis: effects of approved therapies Nintedanib and Pirfenidone Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 Time course of bleomycin-induced pulmonary fibrosis and the antifibrotic effect of losartan Source: Annual Congress 2007 - Mechanisms of injury and repair in fibrotic, idiopathic or infectious lung disease Year: 2007 Anti-inflammatory and anti-fibrotic effects of sirolimus in bleomycin-induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Effects of a neutrophil elastase inhibitor against mediators of acute exacerbation of pulmonary fibrosis: a new therapeutic strategy Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis Year: 2008 Potential therapeutic use of 12-Lipoxygenase inhibitors in the treatment of mucus overproduction in cystic fibrosis Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease Year: 2009 Evaluation of novel LOXL2-selective inhibitors in models of pulmonary fibrosis Source: International Congress 2017 – Cellular signalling pathways in pulmonary fibrosis Year: 2017 GED-0507 as a novel anti-fibrotic treatment option for pulmonary fibrosis Source: International Congress 2018 – Regenerative and anti-fibrotic approaches Year: 2018 The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 The novel oligonucleotide therapeutics PK-7010 for TGF-ß1 ameliorates bleomycin-induced pulmonary fibrosis in mice Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by regulating inflammatory cytokines in bronchoalveolar fluid Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 Therapeutic effect of combination of salvia and ligustrazine on bleomycin-induced pulmonary fibrosis Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 The potential impact of azithromycin in idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (2) 1800628; 10.1183/13993003.00628-2018 Year: 2019 Effects of prednisolone and imatinib mesylate on inflammation and fibrosis in amiodarone-induced pulmonary toxicity in rats Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010